Ipamorelin Blend: What It Is, Common Combinations, and Research Dosages

An ipamorelin blend is a research peptide product that combines ipamorelin, a selective growth hormone secretagogue, with one or more additional peptides such as CJC-1295, tesamorelin, or fragment 176-191 in a single vial. These products are sold strictly for laboratory research, and no combined ipamorelin product is FDA-approved for human use in the United States. This guide covers the common combinations, the reported research dosages, and the quality and safety questions that matter most.

What Ipamorelin Does in a Blend

Ipamorelin is a five-amino-acid peptide that binds the ghrelin receptor (GHS-R1a) and triggers growth hormone release. It is often described as selective because animal and early human data suggest it raises GH with comparatively little effect on cortisol, prolactin, or appetite.

On its own, ipamorelin produces a short, pulse-like GH signal. Ipamorelin and CJC-1295 act on different receptors — ghrelin and GHRH respectively — which is why the pair is frequently described as complementary rather than redundant.

The blend ratio matters as much as the ingredient list. A 10 mg vial split evenly between two peptides delivers a very different amount per administration than a 10 mg vial of ipamorelin alone, so the label total is never the whole story.

Common Ipamorelin Blend Combinations

Most blends on the research market fall into a handful of recognizable categories. The table below summarizes the combinations that appear most often.

Each added peptide changes the profile. CJC-1295 without DAC has a short half-life that pairs naturally with ipamorelin's pulse, while the DAC version produces a sustained signal instead. Tesamorelin is the only component in these blends holding FDA approval, and that approval covers HIV-associated lipodystrophy only.

Reported Research Dosages and Ratios

Dosing information for blends comes from published studies of the individual peptides, not from studies of the blends themselves. Every ratio sold on the market is therefore an extrapolation.

• Ipamorelin alone: 100–300 mcg per administration, one to three times daily, is the range most often cited.
• CJC-1295 without DAC: roughly 100 mcg per administration, commonly paired 1:1 with ipamorelin.
• CJC-1295 with DAC: about 1–2 mg per week in divided doses, far too much to pair 1:1 with ipamorelin.
• Tesamorelin: 1–2 mg daily in the FDA-labeled product, a dose 10 to 20 times higher than a typical ipamorelin dose.

That mismatch is the central practical problem with fixed-ratio vials. A single blend cannot deliver a studied dose of both tesamorelin and ipamorelin at the same time.

A 2x blend tesamorelin 10mg ipamorelin 5mg vial, for example, is a 15 mg total product with a 2:1 ratio in favor of tesamorelin. That ratio is a manufacturing decision, not a finding from a controlled trial.

The most frequently searched formulation is the cjc-1295 no dac ipamorelin 10mg blend dosage, which usually contains 5 mg of each peptide. Reconstituted with 2 mL of bacteriostatic water, that works out to roughly 250 mcg of each peptide per 10-unit mark on a standard insulin syringe — useful arithmetic for planning a measurement, and nothing more.

What Community Discussions Often Cover

Forums and message boards fill the gap left by the lack of blend-specific trials. A typical tesamorelin ipamorelin blend reddit thread tends to focus on injection timing, whether the two peptides compete for the same receptor, and how people space doses around sleep.

Community reports are anecdotal and cannot substitute for controlled data. Self-reported results vary widely, and none of these discussions establish safety or effectiveness for any blend.

Safety, Legal Status, and Quality Concerns

Ipamorelin and every blend containing it are not approved by the FDA for human use. In the United States these products are sold as research chemicals, which means they are not held to the manufacturing, purity, and labeling standards that apply to prescription drugs.

Reported side effects of growth hormone secretagogues include injection-site reactions, headache, flushing, fluid retention, and changes in blood sugar. People with hormone-sensitive conditions, diabetes, or a history of cancer are generally advised to avoid them entirely.

Anyone weighing any peptide should speak with a licensed healthcare professional first. Nothing sold on the research market is a substitute for medical advice or an approved therapy.

How to Evaluate an Ipamorelin Blend for Sale

Quality varies enormously between suppliers. If you search for a tesamorelin ipamorelin blend for sale, the label by itself tells you almost nothing about what is inside the vial.

• Third-party testing: Look for a certificate of analysis from an accredited lab, with lot numbers that match the vial in hand.
• Identity and purity: HPLC purity above 98% plus mass spectrometry confirmation of the peptide sequence are baseline expectations.
• Ratio transparency: The exact milligram amount of each peptide should be printed, not just the total vial size.
• Sterility and endotoxin: For injectable research products, endotoxin testing is a critical quality marker.

A three-component tesamorelin cjc1295 ipamorelin blend raises the same questions with more variables, since each peptide needs its own purity data. Blends that also add fragment 176-191, AOD9604, or other compounds are even harder to verify.

Price should never be the deciding factor. Underdosed and misidentified peptides are common in this market, and no regulatory body is checking the claim printed on the label.